LifeStance Health Group (LFST) to Release Quarterly Earnings on Thursday

LifeStance Health Group (NASDAQ:LFST) will release its earnings data before the market opens on Thursday, November 7th. Analysts expect LifeStance Health Group to post earnings of ($0.07) per share for the quarter. LifeStance Health Group has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, August 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $312.30 million during the quarter, compared to analysts’ expectations of $305.85 million. LifeStance Health Group had a negative return on equity of 10.51% and a negative net margin of 13.05%. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period last year, the firm earned ($0.13) EPS. On average, analysts expect LifeStance Health Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeStance Health Group Stock Up 2.2 %

NASDAQ LFST opened at $6.86 on Wednesday. The stock has a fifty day moving average of $6.84 and a 200-day moving average of $6.17. The stock has a market capitalization of $2.62 billion, a P/E ratio of -16.80 and a beta of 1.24. LifeStance Health Group has a 52 week low of $4.64 and a 52 week high of $9.20. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.22 and a current ratio of 1.22.

Analyst Upgrades and Downgrades

LFST has been the subject of a number of analyst reports. Barclays decreased their price objective on LifeStance Health Group from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Friday, August 9th. UBS Group decreased their price objective on LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating for the company in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, LifeStance Health Group currently has an average rating of “Hold” and a consensus price target of $8.25.

Insiders Place Their Bets

In other LifeStance Health Group news, insider Ann Varanakis sold 5,269 shares of LifeStance Health Group stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $6.28, for a total transaction of $33,089.32. Following the transaction, the insider now directly owns 263,007 shares in the company, valued at approximately $1,651,683.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 6.60% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.